Recently, Jiang et al. demonstrated that acriflavine (ACF), a HIF-1 inhibitor, increased the expression of adiponectin, suggesting its potential as a therapeutic treatment for obesity and type 2 diabetes [21]. Here, HIF1A is linked to type 2 diabetes mellitus.